Sci­ence 37, one of the star­tups that fu­eled the rise in de­cen­tral­ized clin­i­cal tri­als, will go pri­vate and see its one-time $1 bil­lion val­u­a­tion evap­o­rate … ...

Just a few days af­ter pric­ing a $150 mil­lion pub­lic of­fer­ing, Io­vance has now closed with 15% more raised, thanks to … ...

A bill that re­quires the Di­rec­tor of Na­tion­al In­tel­li­gence to de­clas­si­fy new in­for­ma­tion on the ori­gins of Covid-19 passed the House … ...

When Pres­i­dent Joe Biden’s bud­get comes out on Thurs­day, ex­pect to see a big, po­ten­tial­ly mul­ti-bil­lion-dol­lar pro­pos­al to re­al­ly take a crack at cur­ing more … ...

As part of an at­tempt to halt a like­ly new surge of hos­pi­tal­iza­tions and deaths from Omi­cron’s BA.5 sub­vari­ant this fall, the FDA on Wednes­day … ...

Months af­ter No­vavax cel­e­brat­ed its first prof­itable quar­ter as a com­mer­cial com­pa­ny, the Gaithers­burg, MD-based com­pa­ny is back in the red.

De­spite Ugur Sahin’s calls for calm over the Omi­cron vari­ant — mak­ing a much more mea­sured ap­peal than Mod­er­na CEO Stéphane Ban­cel — the BioN­Tech chief is … ...

Alex Gorsky, the CEO whose nine-year tenure at J&J was marred by law­suits over the com­pa­ny’s talc ba­by pow­der and opi­oids, will ...

A whole in­dus­try may have been born out of the spec­tac­u­lar suc­cess of CD19 CAR-T, push­ing the en­ve­lope on next-gen­er­a­tion con­structs hit­ting new tar­gets. But … ...

Pfiz­er’s Covid-19 vac­cine is like­ly to bring in about $26 bil­lion in 2021 rev­enues, which is more than $10 bil­lion more than the bio­phar­ma be­he­moth … ...

As the virus be­hind the Covid-19 pan­dem­ic con­tin­ues to mu­tate in­to sev­er­al vari­ants of con­cern, the com­pa­ny be­hind Eli Lil­ly’s bam­lanivimab an­ti­body treat­ment is look­ing … ...

John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his ...